Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0004153 (atherosclerosis)
 77,401 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 16-year-old male white cockatoo was presented with lethargy and a decreased appetite. Auscultation between the second and third sternal rib revealed a heart murmur, which was confirmed by electrocardiographic and phonocardiographic examination to be systolic, with a shift of the heart axis to -152 degrees. Radiographs showed lack of detail in the cranial part of the abdominal coelom, indicative of ascites and an enlarged cardiac shadow, while ultrasonographic examination revealed pericardial effusion and fluid accumulation in the cavitas peritonealis hepatica. An extra fluid-filled cavity was found at the atrioventricular junction in the right cardiac wall and colour Doppler examination demonstrated a turbulent jetstream of blood into the cavity, originating directly above the aortic valve. Non-selective angiocardiography confirmed the ultrasonographic observations. Findings were indicative of an aneurysm of the a. coronaria dextra (right coronary artery). This was confirmed by necropsy which revealed atherosclerosis to be the underlying cause.
 ...
PMID:Clinical diagnosis of aneurysm of the right coronary artery in a white cockatoo (Cacatua alba). 984 16

Anorexia is common in patients with chronic kidney disease and is a main contributor to the high prevalence of protein-energy wasting in them. The peritoneal dialysis (PD) procedure may further impair appetite by causing abdominal discomfort and also through the absorption of the osmotic agent and other factors. An increased peritoneal solute transport rate has been linked to protein-energy wasting and also to the malnutrition, inflammation, and atherosclerosis syndrome, which has been associated to poor appetite and plays a role in most premature deaths in these patients. The pathogenesis of these associations is unclear. In this review, we discuss the effect of PD, in particular, PD solutions, inflammation, and increased peritoneal solute transport rate, on appetite. We also describe strategies to increase appetite in PD patients.
 ...
PMID:Causes of poor appetite in patients on peritoneal dialysis. 2119 10

Incretin peptides are a group of gastrointestinal hormones that play a prominent role in the regulation of glucose metabolism. Incretin-based therapies (IBTs) have recently emerged as an important treatment option for patients with type 2 diabetes mellitus (T2DM). These pharmaceutical agents may be specially well suited for patients who are overweight or obese with primarily post-meal glucose peaks, and in whom traditional first-line oral agents have failed to maintain adequate glycemic control. There are 2 classes of IBTs: the dipeptidyl peptidase-4 (DPP-4) inhibitors and the glucagon-like peptide 1 (GLP-1) receptor agonists. The ultimate effect of both types of agents is to augment GLP-1 signaling, which results in enhanced glucose-dependent insulin secretion, inhibition of glucagon secretion and decreased appetite. This leads to improved regulation of glucose homeostasis accompanied by either no increase in body weight (with DPP-4 inhibitors) or a reduction (with GLP-1 receptor agonists). GLP-1 inhibits food intake and the increased GLP-1 response may contribute as a satiety signal. Although data regarding the effect of GLP-1 agonists and DPP-4 inhibitors on levels of peptides involved in the regulation of food intake in T2DM are few, an indirect effect of IBT on weight loss is possible (e.g. Exendin-4 induces adiponectin secretion in vitro). Results from animal models indicate reduction of food intake and body weight by GLP-1 agonists, but follow-up studies are required. A growing amount of evidence suggests that these peptides may also impact the cardiovascular system, including beneficial effects on myocardial cells, lipid profiles and blood pressure as well as reduced markers of systemic inflammation and improved endothelial dysfunction. The potential role of these agents in improving components of the metabolic syndrome and retardation of atherosclerosis needs to be fully elucidated. Although IBTs are currently recommended only for use in the early treatment of T2DM, the 'non-glycemic' actions of these drugs may have far reaching therapeutic implications. It is hoped that future studies will elucidate their potential strengths and weaknesses for use in various metabolic conditions.
 ...
PMID:Incretin-based therapies, glucometabolic health and endovascular inflammation. 2432 37